How to Manage Heartburn Cost-Effectively After PPI Failure

TOPLINE:

A decision-support model for managing patients with heartburn in whom proton pump inhibitor (PPI) therapy fails suggests that endoscopy with ambulatory reflux monitoring is the optimal cost-effective approach, matching therapy to phenotype.

METHODOLOGY:

• Researchers compared the cost-effectiveness over 1 year of four strategies for managing patients in whom empirical PPI treatment failed.

• Strategies were PPI optimization without diagnostic testing; endoscopy with PPI optimization to identify erosive reflux disease; endoscopy with PPI discontinuation when no erosive reflux disease was found; and combined endoscopy/ambulatory reflux monitoring and PPI discontinuation as appropriate for the phenotype (ie, erosive disease, nonerosive disease, or functional heartburn).

• All index testing was assumed to be done while patients were off PPI treatment.

TAKEAWAY:

• PPI optimization without testing cost insurers $3784 a year and patients $3128 a year owing to healthcare expenses and lower work productivity associated with suboptimal symptom relief, resulting in a loss of 40 healthy days over the course of the year.

• Endoscopy with PPI optimization lowered insurer costs by $1020 a year and patient costs by $1621 a year, compared with optimization without testing, and added 11 healthy days a year by identifying erosive reflux disease.

• Endoscopy with PPI discontinuation added 11 healthy days a year by identifying patients without erosive reflux disease who did not need PPI therapy.

• Endoscopy with ambulatory reflux monitoring and a trial of PPI discontinuation was the most effective strategy, optimizing phenotype-guided treatment, saving insurers $2183 and patients $2396 a year, and adding 22 healthy days a year.

• The findings support recent clinical practice guidelines from the American Gastroenterological Association and the American College of Gastroenterology.

IN PRACTICE:

“[A]n algorithmic approach to comprehensively stratify erosive and non-erosive reflux disease from functional heartburn combined with a trial of PPI discontinuation for patients without erosive findings provide value to patients and insurers,” the authors write.

SOURCE:

Eric D. Shah, MD, MBA, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, led the study, which was published online September 7 in Clinical Gastroenterology and Hepatology.

LIMITATIONS:

Centers may have limited capacity for routine ambulatory reflux monitoring or may not perform it at all. Single-center and older studies were used for model inputs when no other data were available.

DISCLOSURES:

The study had no specific funding. Shah is supported by a National Institutes of Health grant and disclosed that he has consulted for Salix, Mahana, Neuraxis, Phathom, Takeda, Ardelyx, Sanofi, and GI Supply. Other coauthors have consulted for pharmaceutical and/or biotech companies.

Follow Marilynn Larkin on X: @MarilynnL

For more news, follow Medscape on Facebook, X (formerly known as Twitter), Instagram, and YouTube